Home Cart Sign in  
Chemical Structure| 1223397-11-2 Chemical Structure| 1223397-11-2

Structure of WZB117
CAS No.: 1223397-11-2

Chemical Structure| 1223397-11-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

WZB117 is an inhibitor of Glucose Transporter 1 (GLUT1). It inhibited cell proliferation in lung cancer A549 cells and breast cancer MCF7 cells with an IC50 of approximately 10 μM.

Synonyms: WZB117

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of WZB117

CAS No. :1223397-11-2
Formula : C20H13FO6
M.W : 368.31
SMILES Code : FC1=C(C(OC(C2=CC=CC(O)=C2)=O)=CC=C1)OC(C3=CC=CC(O)=C3)=O
Synonyms :
WZB117
MDL No. :MFCD24387113
InChI Key :FRSWCCBXIHFKKY-UHFFFAOYSA-N
Pubchem ID :46830365

Safety of WZB117

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • GLUT1

    GLUT1, IC50:10μM

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF-7 cells 50 μM 1.5 hours Evaluate the activity of GLUT1 inhibitors, WZB117 showed significant inhibition of glucose uptake PMC9692963
Human erythrocytes 0.1 μM to 7 μM 10 min to 1 min WZB117 reversibly and competitively inhibits erythrocyte 3-O-methylglucose (3MG) uptake with Ki(app) of 6.2 μM. PMC5207184
HEK-293 cells 1.15 ± 0.34 μM (IC50) 20 minutes Evaluate the inhibitory activity and IC50 value of WZB117 on GluN1/GluN3A receptors PMC9218946
Peritoneal macrophages 50 and 100 µM 2–3 hours Evaluate the inhibitory effect of WZB117 on macrophage glycolysis PMC8231859
Human subventricular tumor C3 cells (HSVT-C3) 5 µM 24 and 48 hours Inhibited GLUT1, reduced neurite growth PMC8465431
Neuroblastoma 2a cells (Neuro2a) 5 µM 24 and 48 hours Inhibited GLUT1, reduced neurite growth PMC8465431
Human periodontal ligament cells (PDLCs) 10 μM 24 hours Inhibited GLUT1 expression, reduced mechanical stress-induced RANKL upregulation, thereby suppressing osteoclast differentiation. PMC6093892
SW620 cells 80 μM 24 hours Evaluate the effect of WZB117 on glycolysis activity and mitochondrial respiration in SW620 cells, showing significant inhibition of glycolysis. PMC6085544
SW480 cells 80 μM 24 hours Evaluate the effect of WZB117 on glycolysis activity and mitochondrial respiration in SW480 cells, showing significant inhibition of glycolysis. PMC6085544
HTR8/SVneo cells 20 μM 24 hours To evaluate the effect of WZB117 on ferroptosis in HTR8/SVneo cells under high glucose conditions. Results showed that WZB117 significantly reduced RSL3-induced ferroptosis, indicating that GLUT1 inhibition can protect trophoblast cells from ferroptosis. PMC11660491
Cortical neurons 10 µM 24 hours No effect on cell viability PMC8465431
Cortical astrocytes 5 µM and 10 µM 24 hours Significant decrease in viability at 10 µM PMC8465431
U87 cells 5 µM and 10 µM 24 hours No effect on viability at 5 µM, decreased viability by 28.57% at 10 µM PMC8465431
Chondrocytes 40 μM 3 days Inhibited GLUT1 expression, reducing compression-induced chondrocyte hypertrophy PMC11890221
MCF-10A 93.3 µg/mL 48 hours Evaluate the cytotoxicity of WZB117-OCMC-MET on MCF-10A cells, showing an IC50 of 93.3 µg/mL, indicating low toxicity to normal cells. PMC9962472
MDA-MB-231 8.3 µg/mL 48 hours Evaluate the cytotoxicity of WZB117-OCMC-MET on MDA-MB-231 cells, showing an IC50 of 8.3 µg/mL. PMC9962472
MCF-7 10.2 µg/mL 48 hours Evaluate the cytotoxicity of WZB117-OCMC-MET on MCF-7 cells, showing an IC50 of 10.2 µg/mL. PMC9962472
A549 50 μM 48 hours Inhibition of glucose uptake and glycolysis, but with minimal impact on the viability of ADC cell lines PMC5458561
HCC2814 50 μM 48 hours Inhibition of glucose uptake and glycolysis, significantly reducing the viability of SqCC cell lines PMC5458561
HCC1588 50 μM 48 hours Inhibition of glucose uptake and glycolysis, significantly reducing the viability of SqCC cell lines PMC5458561
HCC95 50 μM 48 hours Inhibition of glucose uptake and glycolysis, significantly reducing the viability of SqCC cell lines PMC5458561
SK-MEL-28 113.91 μM 48 hours To evaluate the inhibitory effect of WZB117 on SK-MEL-28 cell proliferation, results showed that WZB117 inhibited cell proliferation in a dose- and time-dependent manner. PMC9524253
A375 116.85 μM 48 hours To evaluate the inhibitory effect of WZB117 on A375 cell proliferation, results showed that WZB117 inhibited cell proliferation in a dose- and time-dependent manner. PMC9524253
MDA-MB-231 cells 60 μM 48 hours WZB117 inhibits glucose uptake in MDA-MB-231 cells and shows synergistic growth inhibition and apoptosis induction when combined with MK-2206. PMC6856645
MCF-7 cells 60 μM 48 hours WZB117 inhibits glucose uptake in MCF-7 cells and shows synergistic growth inhibition and apoptosis induction when combined with MK-2206. PMC6856645
GIST-T1/IM-R cells 10 µM 72 hours WZB117 significantly downregulated AKT phosphorylation and Bcl-2 expression, and combined use with imatinib showed synergistic growth inhibition effects in apoptosis assays. PMC8600406
SKOV3 cells 100 μM 90 minutes Evaluate the activity of GLUT1 inhibitors, WZB117 showed significant inhibition of glucose uptake PMC9692963
COS-7 cells 100 μM 90 minutes Evaluate the activity of GLUT1 inhibitors, WZB117 showed significant inhibition of glucose uptake PMC9692963
CHO cells 3 μM Validate the inhibitory activity of WZB117 on GluN1/GluN3A receptors PMC9218946
HEK293 cells 0.1 μM to 13.32 μM WZB117 inhibits GLUT1- and GLUT3-mediated 2-deoxy-D-glucose (2DG) uptake with Ki(app) of ~10 μM but is a more potent inhibitor of GLUT4-mediated uptake (Ki(app) of 0.2 μM). PMC5207184

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rat Postnatal day 5 rats Cerebral cortex injection 10 µM Single injection, lasting 72 hours Inhibited GLUT1, reduced neurite length and branching PMC8465431
Nude mice HCC1588 and HCC2814 xenograft models Intraperitoneal injection 10 mg/kg Once daily for 3-4 weeks GLUT1 inhibition significantly suppressed SqCC tumor growth but had no significant effect on ADC tumor growth PMC5458561
C57BL/6 mice Orthodontic tooth movement (OTM) model Intraperitoneal injection 10 mg/kg Every other day for 7 days Inhibited GLUT1 activity, reduced orthodontic tooth movement distance and osteoclastic activities. PMC6093892
C57BL/6J mice STZ-induced gestational diabetes model Intraperitoneal injection 10 mg/kg Every other day from E13.5 to E18.5 To evaluate the effect of WZB117 on fetal growth restriction in STZ-induced gestational diabetes mouse model. Results showed that WZB117 treatment significantly improved fetal weight and crown-rump length, reduced placental ferroptosis markers, indicating that GLUT1 inhibition can ameliorate gestational diabetes-associated fetal growth restriction. PMC11660491
Nude mice ICCA patient-derived xenograft (PDX) model Intraperitoneal injection 10 mg/kg Once daily for 6 weeks WZB117 inhibited the tumor growth of the PDX#4 models but did not inhibit tumor growth in the PDX#1 group. PMC7018977
Sprague-Dawley (SD) rats TMJ degeneration model Intra-articular injection 10 mg/ml Daily for the duration of the experiment Inhibited GLUT1 expression, reducing chondrocyte hypertrophy and O-GlcNAcylation levels PMC11890221
Mice Orthotopic model of pancreatic ductal adenocarcinoma Oral 250 ppm (equivalent to a 50 mg/kg daily dose) Once daily for 7 days Evaluate the effect of WZB117 on tumor burden, results showed WZB117 significantly reduced tumor burden PMC8231859

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.72mL

0.54mL

0.27mL

13.58mL

2.72mL

1.36mL

27.15mL

5.43mL

2.72mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories